Opiant Pharmaceuticals, Inc. Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer
“I am delighted to welcome Dr. Skolnick to the Opiant team, and look forward to his contributions as we advance development of our pipeline of novel substance abuse treatments,” said
“I am honored to have the opportunity to lead Opiant’s talented R&D team and to help fulfill the Company’s mission of introducing new treatment options to combat addictions,” said Dr. Skolnick. “I am eager to guide the preclinical and clinical development of the Company’s promising pipeline with the goal of bringing new treatments to the people who need them.”
Dr. Skolnick joins Opiant from the
Dr. Skolnick earned his Ph.D. from The
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.
CONTACT INFORMATION: Corporate Contact: Investor.firstname.lastname@example.org Media:
Susan FormanDGI email@example.com 212-825-3210 Investors: Glenn GarmontSenior Vice President Argot Partnersglenn@argotpartners.com 212-600-1902